英派药业-B（07630）今日盘中大涨65.67%，引起了市场的广泛关注。
消息面上，该公司今日正式在香港联交所主板挂牌上市。根据公布的配发结果，英派药业-B的香港公开发售部分获得了约2282.4倍的巨额超额认购，国际发售部分也获得约24.58倍超额认购。这一极高的认购倍数和仅为约1.5%的一手中签率，充分反映了投资者对其发展前景的强烈信心和市场的热烈追捧，是推动其股价在上市首日大幅上涨的核心原因。
公开资料显示，英派药业是一家处于商业化阶段的生物技术公司，致力于在全球范围内开发基于合成致死机制的精准抗癌疗法。公司核心产品塞纳帕利已于2025年1月在中国获批用于卵巢癌一线维持治疗。公司目前拥有1款商业化产品、4款临床阶段产品及7款临床前产品，管线覆盖PARP1/2、ATR、WEE1等多个关键合成致死靶点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.